Literature DB >> 24744578

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Hui-Yan Luo1, Rui-Hua Xu1.   

Abstract

Colorectal cancer (CRC) is one of the most common human malignant diseases and the second leading cause of cancer-related deaths worldwide. The treatment of advanced CRC has improved significantly in recent years. With the emergence of two targeted antibodies, cetuximab (Erbitux), an anti-epidermal growth factor receptor monoclonal antibody and bevacizumab (Avastin), a vascular endothelial growth factor monoclonal antibody, the treatment of metastatic CRC has entered the era of personalized therapy. Predictive and prognostic biomarkers have, and will continue to, facilitate the selection of suitable patients and the personalization of treatment for metastatic CRC (mCRC). In this review, we will focus primarily on the important progresses made in the personalized treatment of mCRC and discuss the potentially novel predictive and prognostic biomarkers for improved selection of patients for anti-cancer treatment in the future.

Entities:  

Keywords:  Advanced colorectal cancer; Biomarker; Predictive; Prognostic; Target therapy

Mesh：

Substances：

Year:  2014        PMID： 24744578      PMCID： PMC3983442          DOI： 10.3748/wjg.v20.i14.3858

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  134 in total

1.  Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.

Authors:  Salvatore Artale; Andrea Sartore-Bianchi; Silvio Marco Veronese; Valentina Gambi; Carolina Silvia Sarnataro; Marcello Gambacorta; Calogero Lauricella; Salvatore Siena
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

Review 2.  The epidermal growth factor receptor as a target for colorectal cancer therapy.

Authors:  A Craig Lockhart; Craig Lockhart; Jordan D Berlin
Journal:  Semin Oncol       Date:  2005-02       Impact factor: 4.929

3.  Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer.

Authors:  Mariusz Koda; Joanna Reszec; Mariola Sulkowska; Luiza Kanczuga-Koda; Stanislaw Sulkowski
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

4.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

Authors:  Mauro Moroni; Silvio Veronese; Silvia Benvenuti; Giovanna Marrapese; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Marcello Gambacorta; Salvatore Siena; Alberto Bardelli
Journal:  Lancet Oncol       Date:  2005-05       Impact factor: 41.316

Review 5.  Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Authors:  Joanne Harding; Barbara Burtness
Journal:  Drugs Today (Barc)       Date:  2005-02       Impact factor: 2.245

6.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Authors:  Ki Young Chung; Jinru Shia; Nancy E Kemeny; Manish Shah; Gary K Schwartz; Archie Tse; Audrey Hamilton; Dorothy Pan; Deborah Schrag; Lawrence Schwartz; David S Klimstra; Daniel Fridman; David P Kelsen; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2005-01-27       Impact factor: 44.544

7.  Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer.

Authors:  Masanori Yoshino; Toshiyuki Ishiwata; Masanori Watanabe; Osamu Komine; Tetsuo Shibuya; Akira Tokunaga; Zenya Naito
Journal:  Oncol Rep       Date:  2005-02       Impact factor: 3.906

8.  Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

Authors:  Nicola Personeni; Steffen Fieuws; Hubert Piessevaux; Gert De Hertogh; Jef De Schutter; Bart Biesmans; Wendy De Roock; An Capoen; Maria Debiec-Rychter; Jean-Luc Van Laethem; Marc Peeters; Yves Humblet; Eric Van Cutsem; Sabine Tejpar
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

9.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.

Authors:  Evangelia Razis; Evangelos Briasoulis; Eleni Vrettou; Dimosthenis V Skarlos; Dimitrios Papamichael; Ioannis Kostopoulos; Epaminontas Samantas; Ioannis Xanthakis; Mattheos Bobos; Eleni Galanidi; Maria Bai; Ioanna Gikonti; Alona Koukouma; Georgia Kafiri; Pavlos Papakostas; Konstantine T Kalogeras; Paris Kosmidis; George Fountzilas
Journal:  BMC Cancer       Date:  2008-08-13       Impact factor: 4.430
View more
  29 in total

Review 1.  Molecular markers predictive of chemotherapy response in colorectal cancer.

Authors:  Stacey Shiovitz; William M Grady
Journal:  Curr Gastroenterol Rep       Date:  2015-02

Review 2.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

3.  Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.

Authors:  Seon Ae Roh; In Ja Park; Yong Sik Yoon; Yi Hong Kwon; Jin Hwa Chung; Tae Won Kim; Dong Hyung Cho; Byung Ho Lim; Seon Kyu Kim; Seon Young Kim; Yong Sung Kim; Jin Cheon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-13       Impact factor: 4.553

Review 4.  Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

Authors:  Gustaw Lech; Robert Słotwiński; Maciej Słodkowski; Ireneusz Wojciech Krasnodębski
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

5.  Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.

Authors:  A Makkouk; V Sundaram; C Chester; S Chang; A D Colevas; J B Sunwoo; H Maecker; M Desai; H E Kohrt
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

Review 6.  The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.

Authors:  Marina De Rosa; Daniela Rega; Valeria Costabile; Francesca Duraturo; Antonello Niglio; Paola Izzo; Ugo Pace; Paolo Delrio
Journal:  Therap Adv Gastroenterol       Date:  2016-08-07       Impact factor: 4.409

7.  A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

Authors:  Johanna C Bendell; Howard Hochster; Lowell L Hart; Irfan Firdaus; Joseph R Mace; Joshua J McFarlane; Mark Kozloff; Daniel Catenacci; Jessie J Hsu; Stephen P Hack; David S Shames; See-Chun Phan; Hartmut Koeppen; Allen L Cohn
Journal:  Oncologist       Date:  2017-02-16

8.  Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.

Authors:  Vibeke Andersen; Katrine Svenningsen; Lina Almind Knudsen; Axel Kornerup Hansen; Uffe Holmskov; Allan Stensballe; Ulla Vogel
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

9.  A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.

Authors:  Long Bai; Feng Wang; Dong-Sheng Zhang; Cong Li; Ying Jin; De-Shen Wang; Dong-Liang Chen; Miao-Zhen Qiu; Hui-Yan Luo; Zhi-Qiang Wang; Yu-Hong Li; Feng-Hua Wang; Rui-Hua Xu
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

10.  Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.

Authors:  Petra Martin; Sinead Noonan; Michael P Mullen; Caitriona Scaife; Miriam Tosetto; Blathnaid Nolan; Kieran Wynne; John Hyland; Kieran Sheahan; Giuliano Elia; Diarmuid O'Donoghue; David Fennelly; Jacintha O'Sullivan
Journal:  BMC Cancer       Date:  2014-11-27       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.